1. Home
  2. WKC vs GPCR Comparison

WKC vs GPCR Comparison

Compare WKC & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo World Kinect Corporation

WKC

World Kinect Corporation

HOLD

Current Price

$26.02

Market Cap

1.4B

Sector

Energy

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$63.98

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
WKC
GPCR
Founded
1984
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
WKC
GPCR
Price
$26.02
$63.98
Analyst Decision
Hold
Strong Buy
Analyst Count
4
11
Target Price
$28.75
$97.90
AVG Volume (30 Days)
1.0M
2.4M
Earning Date
02-19-2026
11-06-2025
Dividend Yield
3.15%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$37,648,100,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.71
$13.22
52 Week High
$31.54
$94.90

Technical Indicators

Market Signals
Indicator
WKC
GPCR
Relative Strength Index (RSI) 70.68 57.31
Support Level $23.42 $61.99
Resistance Level $23.87 $70.40
Average True Range (ATR) 0.51 4.16
MACD 0.27 -1.33
Stochastic Oscillator 96.43 36.59

Price Performance

Historical Comparison
WKC
GPCR

About WKC World Kinect Corporation

World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. The company earns the majority of its revenue from the Aviation segment.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: